MVIR — Medivir AB Share News
0.000.00%
Last trade - 00:00- SEK906.04m
- SEK763.34m
- SEK8.51m
Brief: Medivir Appoints Jens Lindberg As CEO
Brief: Medivir Q2 EBITDA Loss Widens To SEK 17.1 Mln
Brief: Medivir Strengthens Business Development Potential Of Remetinostat Through Renegotiated Multi-Party Agreement
Brief: Medivir: Positive Data From Remetinostat Phase II Study In Basal Cell Carcinoma Published In Clinical Cancer Research
Brief: Medivir Says Positive Results From Investigator-Initiated Phase II Clinical Study Of Remetinostat In Patients With Squamous Cell Carcinoma Published
Brief: Medivir Q1 EBITDA Loss Narrows To SEK 7.2 Mln
Brief: Medivir Appoints Magnus Christensen As Interim CEO
Brief: Medivir Says Yilmaz Mahshid Leaves Position As CEO
Brief: Medivir Q4 EBITDA Loss Narrows To SEK 10.6 Million
Brief: Medivir Enters Into Licensing Agreement With Ubiquigent For Preclinical Program USP7
Brief: Medivir Announces Final Outcome Of The Oversubscribed Rights Issue And Resolves On Over-Allotment
Brief: Medivir Proposes Directed Issue SEK 28 Mln To Linc
Brief: Medivir Presents MIV-818 Data At ASCO Gastrointestinal Cancers Symposium
Brief: Medivir Enters Into Licensing Agreement With IGM Biosciences For Birinapant
Brief: Medivir Enters Into Exclusive Licensing Agreement With IGM Biosciences To Develop Birinapant
Brief: Medivir: Renegotiated Agreement With Tetralogic Regarding Birinapant
Brief: Medivir Resolves On Rights Issue Of About SEK 170 Mln
Brief: Medivir Q3 EBITDA Swings To Profit Of SEK 5.2 Million
Brief: Medivir Q2 EBITDA Loss At SEK 12.4 Million